BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hou Q, Huang Y, Zhu Z, Liao L, Chen X, Han Q, Liu F. Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways. BMC Complement Altern Med 2019;19:337. [PMID: 31775739 DOI: 10.1186/s12906-019-2749-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhen Z, Xia L, You H, Jingwei Z, Shasha Y, Xinyi W, Wenjing L, Xin Z, Chaomei F. An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome. Front Pharmacol 2021;12:746923. [PMID: 34916934 DOI: 10.3389/fphar.2021.746923] [Reference Citation Analysis]
2 Jiang J, Chen Y, Hu Z, Li H, Ye J, Yu Z, Tang H. Effectiveness of Tong-Xie-Yao-Fang combined with Si-Ni-San for irritable bowel syndrome: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25198. [PMID: 33726014 DOI: 10.1097/MD.0000000000025198] [Reference Citation Analysis]
3 Xie Y, Zhan X, Tu J, Xu K, Sun X, Liu C, Ke C, Cao G, Zhou Z, Liu Y. Atractylodes oil alleviates diarrhea-predominant irritable bowel syndrome by regulating intestinal inflammation and intestinal barrier via SCF/c-kit and MLCK/MLC2 pathways. J Ethnopharmacol 2021;272:113925. [PMID: 33592255 DOI: 10.1016/j.jep.2021.113925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang Y, Huang YQ, Zhu SL, Zhang CR, Chen XL, Hou QK, Liu FB. Efficacy of Tong-Xie-Yao-Fang granule and its impact on whole transcriptome profiling in diarrhea-predominant irritable bowel syndrome patients: study protocol for a randomized controlled trial. Trials 2020;21:908. [PMID: 33143731 DOI: 10.1186/s13063-020-04833-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Choo J, Heo G, Pothoulakis C, Im E. Posttranslational modifications as therapeutic targets for intestinal disorders. Pharmacol Res 2021;165:105412. [PMID: 33412276 DOI: 10.1016/j.phrs.2020.105412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Xing Y, Xue S, Wu J, Zhou J, Xing F, Li T, Nie X. Serum Exosomes Derived from Irritable Bowel Syndrome Patient Increase Cell Permeability via Regulating miR-148b-5p/RGS2 Signaling in Human Colonic Epithelium Cells. Gastroenterol Res Pract 2021;2021:6655900. [PMID: 34221007 DOI: 10.1155/2021/6655900] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Lai Y, Liang X, Fan H, Liu Y, Zheng L, Lu W, Sun Y, Huang D, Liu X, Zhang L, Zuo D, Shou Z, Tang Q, Wang Y, Li Z, Jiang Z, Zang S, Huang H, Tang Z, Li Q, Xiao J. Assessing the post-treatment therapeutic effect of tongxie in irritable bowel syndrome: a randomized controlled trial. Complement Ther Med 2022;:102839. [PMID: 35483627 DOI: 10.1016/j.ctim.2022.102839] [Reference Citation Analysis]
8 Zhang C, Huang Y, Li P, Chen X, Liu F, Hou Q. Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction. BMC Complement Med Ther 2020;20:279. [PMID: 32928188 DOI: 10.1186/s12906-020-03059-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Li L, Zhong S, Cheng B, Qiu H, Hu Z. Cross-Talk between Gut Microbiota and the Heart: A New Target for the Herbal Medicine Treatment of Heart Failure? Evid Based Complement Alternat Med 2020;2020:9097821. [PMID: 32328141 DOI: 10.1155/2020/9097821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Huang H, Zhao P, Xi M, Li F, Ji L. Mechanism of QingHuaZhiXie Prescription Regulating TLR4-IECs Pathway in the Intervention of Diarrhea Predominant Irritable Bowel Syndrome. Evid Based Complement Alternat Med 2021;2021:5792130. [PMID: 34795785 DOI: 10.1155/2021/5792130] [Reference Citation Analysis]
11 Shao YY, Guo Y, Feng XJ, Liu JJ, Chang ZP, Deng GF, Xu D, Gao JP, Hou RG. Oridonin Attenuates TNBS-induced Post-inflammatory Irritable Bowel Syndrome via PXR/NF-κB Signaling. Inflammation 2021;44:645-58. [PMID: 33125572 DOI: 10.1007/s10753-020-01364-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]